Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Safety and PK of EC-18 in Healthy Male Volunteers
NCT02532712Phase 1Completed
- Sponsor
- Enzychem Lifesciences
- Start
- Mar 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mosedipimod in chemotherapy-induced neutropenia (CIN) (16 arms), sponsored by Enzychem Lifesciences. Primary endpoints: Number and severity of Adverse Events up to 30 days and Vital signs, physical examination, clinical laboratory tests, ECG up to 60 days. Started Mar 2015; status: completed.
02
Drugs
mosedipimod
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT02532712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532712.